{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:52:58Z","timestamp":1788839578131,"version":"build-2803163510"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Given high rates of locoregional control after definitive management of head and neck squamous cell carcinoma (HNSCC), better methods are needed to project distant metastasis (DM) risk. Tumor hypoxia on 18<\/jats:sup>F-fluoromisonidazole (FMISO) positron emission tomography (PET) is associated with locoregional failure, but data demonstrating an association with DM are limited.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine whether tumor hypoxia on FMISO PET is associated with DM risk after chemoradiotherapy (CRT) for HNSCC.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study assessed patients with HNSCC enrolled in 2 prospective clinical trials at a single academic referral center from 2004 to 2021 in which participants received FMISO PET before and during CRT. Data analysis occurred from May 2023 to May 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>FMISO PET scans before and 1 to 2 weeks after starting CRT were evaluated for tumor hypoxia by nuclear medicine physicians.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was DM, defined as biopsy-proven HNSCC outside the primary site and regional lymph nodes. Time to DM was modeled with competing risk regression, with death as a competing risk. Overall survival (OS) was assessed secondarily and modeled with Cox regression.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 281 patients (median [range] age at CRT, 58.7 [25.5-85.6] years; 251 male [89.3%]) included in this study, 242 (86.1%) had oropharyngeal primary cancer, and 266 (94.7%) had human papillomavirus\u2013positive disease. Of all patients, 217 (77.2%) had T stage 1 or 2, and 231 patients (82.2%) had N stage 2b or less. De-escalated 30 Gy CRT was delivered to 144 patients (51.2%), and the remainder received standard 70 Gy CRT. On FMISO PET examination, 73 patients (26.0%) had hypoxia-negative disease before CRT, 138 patients (49.1%) had hypoxia-positive disease before CRT and then hypoxia-negative disease during CRT, and 70 patients (24.9%) persistently had hypoxia-positive disease before and during CRT. At a median (IQR) 58 (46-91) months of follow-up, 12 DM events and 22 deaths were observed. Persistent intratreatment hypoxia was associated with increased DM risk (hazard ratio, 3.51; 95% CI, 1.05-11.79; P<\/jats:italic>\u2009=\u2009.04) and worse OS (hazard ratio, 2.66; 95% CI, 1.14-6.19; P<\/jats:italic>\u2009=\u2009.02). No patients with hypoxia-negative disease before CRT experienced DM.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study using pooled analysis of prospective nonrandomized clinical trials incorporating FMISO PET in the definitive management of HNSCC, persistent intratreatment hypoxia was associated with increased risk of DM and worse OS. Conversely, all patients with hypoxia-negative disease before treatment remained free of DM. These findings suggest that pretreatment and intratreatment FMISO PET results may serve as biomarkers for DM risk and aid in identifying candidates for escalated therapeutic strategies.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.36407","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T15:32:25Z","timestamp":1727710345000},"page":"e2436407","source":"Crossref","is-referenced-by-count":9,"title":["Tumor Hypoxia on 18<\/sup>F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma"],"prefix":"10.1001","volume":"7","author":[{"given":"Chengcheng","family":"Gui","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Wray","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Deasy","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Grkovski","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Humm","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Riaz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"issue":"11","key":"zoi241072r1","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1001\/jamaoncol.2017.0973","article-title":"Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques.","volume":"3","author":"Leeman","year":"2017","journal-title":"JAMA Oncol"},{"key":"zoi241072r2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.oraloncology.2018.11.023","article-title":"Patterns of distant metastasis in head and neck cancer at presentation: implications for initial evaluation.","volume":"88","author":"Liu","year":"2019","journal-title":"Oral Oncol"},{"issue":"29","key":"zoi241072r3","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.2015.61.2994","article-title":"Advances in radiotherapy for head and neck cancer.","volume":"33","author":"Gr\u00e9goire","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10212","key":"zoi241072r4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"zoi241072r5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia\u2013a key regulatory factor in tumour growth.","volume":"2","author":"Harris","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"6282","key":"zoi241072r6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aaf4405","article-title":"Hypoxic control of metastasis.","volume":"352","author":"Rankin","year":"2016","journal-title":"Science"},{"issue":"10","key":"zoi241072r7","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1089\/ars.2013.5378","article-title":"The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.","volume":"21","author":"Walsh","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"zoi241072r8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.semnuclmed.2020.05.003","article-title":"Imaging of tumor hypoxia for radiotherapy: current status and future directions.","volume":"50","author":"Busk","year":"2020","journal-title":"Semin Nucl Med"},{"issue":"10","key":"zoi241072r9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/09553000601002324","article-title":"Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.","volume":"82","author":"Tatum","year":"2006","journal-title":"Int J Radiat Biol"},{"issue":"2","key":"zoi241072r10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0360-3016(96)00325-2","article-title":"Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients.","volume":"36","author":"Rasey","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi241072r11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijrobp.2007.08.036","article-title":"Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.","volume":"70","author":"Nehmeh","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"zoi241072r12","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-017-3720-6","article-title":"Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer.","volume":"44","author":"Grkovski","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"zoi241072r13","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.2967\/jnumed.116.188649","article-title":"Multiparametric imaging of tumor hypoxia and perfusion with 18F-fluoromisonidazole dynamic PET in head and neck cancer.","volume":"58","author":"Grkovski","year":"2017","journal-title":"J Nucl Med"},{"issue":"13","key":"zoi241072r14","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2005.05.2878","article-title":"Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman radiation oncology group study 98.02.","volume":"24","author":"Rischin","year":"2006","journal-title":"J Clin Oncol"},{"key":"zoi241072r15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.radonc.2022.03.021","article-title":"Dose escalation to hypoxic subvolumes in head and neck cancer: a randomized phase II study using dynamic [18F]FMISO PET\/CT.","volume":"171","author":"Welz","year":"2022","journal-title":"Radiother Oncol"},{"issue":"1","key":"zoi241072r16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijrobp.2016.04.027","article-title":"Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma.","volume":"96","author":"Lee","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"zoi241072r17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djaa184","article-title":"Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial.","volume":"113","author":"Riaz","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"zoi241072r18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1200\/JCO.23.01308","article-title":"Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma.","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi241072r19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.radonc.2017.04.004","article-title":"Prognostic value of dynamic hypoxia PET in head and neck cancer: results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.","volume":"124","author":"Welz","year":"2017","journal-title":"Radiother Oncol"},{"key":"zoi241072r20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.radonc.2018.09.008","article-title":"FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.","volume":"130","author":"Bandurska-Luque","year":"2019","journal-title":"Radiother Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824210\/gui_2024_oi_241072_1727207870.92574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T15:32:26Z","timestamp":1727710346000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.36407","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}